"Schutzov\u00E1, Miroslava" . "Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse"@en . . . . . "15110" . "RIV/61989592:15110/09:10224290!RIV12-MSM-15110___" . "Mayer, Ji\u0159\u00ED" . . . . "H\u00E1jek, Roman" . "[F52D86A61D0D]" . "Krej\u010D\u00ED, Marta" . "\u0160\u010Dudla, Vlastimil" . "Autologous stem cell transplantation (autoSCT) has an important role in the treatment of patients with symptomatic multiple myeloma (MM). Treatment options for myeloma have expanded in the past decade, and it seems that patients who are treated with novel drugs such as thalidomide and bortezomib for relapse after autoSCT have longer overall survival (OS). Herein, we describe the long-term outcome of a cohort of 185 patients with newly diagnosed MM treated with autoSCT. We have analyzed factors that might predict for long-term survival. Conclusion: According to our results, the achievement of CR after transplantation, ISS stage other than III, and administration of thalidomide or bortezomib in posttransplantation relapse were significant parameters favoring long-term posttransplantation survival." . "6" . "Pour, Lud\u011Bk" . . "9" . . . "1557-9190" . "15"^^ . "Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse"@en . "Tothov\u00E1, Elen" . "K\u0159ivanov\u00E1, Andrea" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "7"^^ . . . "Zahradov\u00E1, Lenka" . . "324125" . . . "Vorl\u00ED\u010Dek, Ji\u0159\u00ED" . "1"^^ . "RIV/61989592:15110/09:10224290" . . "Buchler, Tpm\u00E1\u0161" . "Kr\u00E1lov\u00E1, Dana" . "Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse" . "Autologous stem cell transplantation (autoSCT) has an important role in the treatment of patients with symptomatic multiple myeloma (MM). Treatment options for myeloma have expanded in the past decade, and it seems that patients who are treated with novel drugs such as thalidomide and bortezomib for relapse after autoSCT have longer overall survival (OS). Herein, we describe the long-term outcome of a cohort of 185 patients with newly diagnosed MM treated with autoSCT. We have analyzed factors that might predict for long-term survival. Conclusion: According to our results, the achievement of CR after transplantation, ISS stage other than III, and administration of thalidomide or bortezomib in posttransplantation relapse were significant parameters favoring long-term posttransplantation survival."@en . "Adam, Zden\u011Bk" . "Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse" . "Thalidomide; International Staging System; Durie-Salmon; complete response; bortezomib"@en . "Koza, Vladim\u00EDr" . "Sandeck\u00E1, Viera" . "Clinical Lymphoma Myeloma" . "I" .